Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
- PMID: 35645701
- PMCID: PMC9134213
- DOI: 10.3389/ijph.2022.1604621
Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
Keywords: HPV genotyping; HPV prevalence; HPV screening; HPV vaccination; cervical cancer screening.
Conflict of interest statement
Authors BWBC and VYM were employed by the company Becton, Dickinson and Company. Author JA was employed by the company Salud Digna A.C. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem (2021). Available from: https://www.who.int/publications/i/item/9789240014107 (Accessed Sep 22, 2021).
-
- Asti L, Hopley C, Avelis C, Bartsch SM, Mueller LE, Domino M, et al. The Potential Clinical and Economic Value of a Human Papillomavirus Primary Screening Test that Additionally Identifies Genotypes 31, 45, 51, and 52 Individually. Sex Trans Dis (2021) 48(5):370–80. 10.1097/olq.0000000000001327 - DOI - PMC - PubMed
